Logo Image
Opinion|Videos|October 11, 2024

Complement Inhibitors in NMOSD

Key Takeaways

  • Ravulizumab, a complement inhibitor, is FDA-approved for NMOSD, offering a longer half-life than eculizumab, allowing for extended dosing intervals.
  • The standard dosing regimen for ravulizumab includes an initial loading dose followed by maintenance doses every eight weeks.
SHOW MORE

Sean Pittock, MD, discusses how complement inhibitors are positioned in the treatment landscape of neuromyelitis optica spectrum disorder, providing an overview of ravulizumab, the most recent FDA-approved treatment, including its development rationale, half-life, dosing regimen, and new signals from the recently presented 138-week long-term extension data at EAN 2024.

Episodes in this series

Video content above is prompted by the following:

  1. Where do complement inhibitors fit in the treatment landscape of neuromyelitis optica spectrum disorder (NMOSD)? Which complement inhibitors are approved for NMOSD?
  2. Please provide an overview of ravulizumab, the most recent FDA-approved treatment for NMOSD, the rationale for its development, half-life, and dosing regimen.
  3. Long-term extension (138-week) data with ravulizumab were recently presented at EAN 2024. 
  4. Are there any new signals in the long-term extension study?

Latest CME

Shining a Light on an Ultra-Rare Disease – A Closer Look at Thymidine Kinase 2 Deficiency (TK2d)
Multimedia

Shining a Light on an Ultra-Rare Disease – A Closer Look at Thymidine Kinase 2 Deficiency (TK2d)

Zarazuela Zolkipli-Cunningham, MBChB, MRCP; Mary Kay Koenig, MD; Perry Shieh, MD, PhD, FAAN, FANA

View more
Expert Illustrations & Commentaries™: Visualizing the Role of Dystrophin Dysregulation as a Therapeutic Target in Duchenne Muscular Dystrophy and MD STARnet
Video

Expert Illustrations & Commentaries™: Visualizing the Role of Dystrophin Dysregulation as a Therapeutic Target in Duchenne Muscular Dystrophy and MD STARnet

Anne M. Connolly, MD, FAAN; Amy Moore, PhD

View more
Unlocking the Future of Glioma Care: Integrating Recent Advances to Personalize Treatment
Video

Unlocking the Future of Glioma Care: Integrating Recent Advances to Personalize Treatment

Vinay K. Puduvalli, MD; Manmeet Ahluwalia, MD, MBA, FASCO; Girish Dhall, MD

View more
From Clue to Care: Rapid Recognition and Coordinated Management of Paraneoplastic LEMS in SCLC
Video

From Clue to Care: Rapid Recognition and Coordinated Management of Paraneoplastic LEMS in SCLC

Millie Das, MD; Wade Iams, MD, MSCI; Ruham Nasany, MD

View more
Community Collab: The Evolving Role of FcRN Inhibitors in the Management of Generalized Myasthenia Gravis (gMG)
Multimedia

Community Collab: The Evolving Role of FcRN Inhibitors in the Management of Generalized Myasthenia Gravis (gMG)

James F. Howard Jr, MD, FAAN; Tuan Vu, MD

View more
Collaborating Across the Continuum™: Integrating Novel Therapies Into Multidisciplinary Treatment Plans for Generalized Myasthenia Gravis
Video

Collaborating Across the Continuum™: Integrating Novel Therapies Into Multidisciplinary Treatment Plans for Generalized Myasthenia Gravis

Abigail Schwaede, MD; Alexis Lizarraga, MD, MS

View more
Community Collab™: Identifying the Role of Complement Inhibitors in the Management of Generalized Myasthenia Gravis
Video

Community Collab™: Identifying the Role of Complement Inhibitors in the Management of Generalized Myasthenia Gravis

James F. Howard Jr, MD, FAAN; Tuan Vu, MD

View more
From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS
Video

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

Charu Aggarwal, MD, MPH, FASCO; Erminia Massarelli, MD, PhD, MS; Ruham Nasany, MD

View more